Phase 4
Completed N=34
Bone Health in Aging HIV Infected Women
Osteoporosis · HIV · Menopause
Source: ClinicalTrials.gov NCT02815566 ↗
Enrolled (actual)
34
Serious AEs
4.1%
Results posted
Jan 2023
Primary outcomePrimary: Percent Change in Bone Mineral Density From Baseline at the Lumbar Spine — 1.97; -2.32; 2.33; 0.7 Percent Change
◆ Published Evidence
Emerging
8citations · ~3 / year
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Summary
Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks.
Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). .
Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96.
Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96.
Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
Linked Publications
-
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Bone Mineral Density From Baseline at the Lumbar Spine |
1.97; -2.32; 2.33; 0.7 | — |
| SECONDARY % Change in Bone Mineral Density From Baseline at the Femoral Neck |
1.46; 0.22; 2.33; 0.70 | — |
Eligibility Criteria
Inclusion Criteria
- Biological female aged 40-60
- Documented HIV-1 infection
- Peri-menopausal ( as documented by history).
- Signed Informed Consent Form and willing to comply with the protocol.
- Receiving a cART regimen containing a ritonavir boosted PI (darunavir, atazanavir, lopinavir,) or an NNRTI (efavirenz, nevirapine or rilpivirine) or an integrase inhibitor (dolutegravir or raltegravir or elvitegravir) in combination with TDF-FTC for > 24 weeks.
- Stable viral suppression (plasma HIV-RNA 24 weeks). Single viral blip 20%) based on country specific FRAX
- Current treatment with active bone medications- bisphosphonates, denosumab, calcitonin, raloxifene, teriparatide, strontium
- Current use of systemic steroids ( inhaled steroids permitted) or chemotherapeutic agents
- Acute viral hepatitis
- Chronic hepatitis C with liver transaminases >5 x ULN or expected to require treatment for hepatitis C during the trial period.
- Any investigational ARV within 30 days.
- Dialysis or renal insufficiency (creatinine clearance 35% direct bilirubin), or the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices.
- Pregnant or breastfeeding
- Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 amylase, creatinine phosphokinase, or lipid elevation.
- Any condition (including illicit drug use or alcohol abuse) or lab results which, in the investigator's opinion, interfere with assessments or completion of the trial.
Data sourced from ClinicalTrials.gov (NCT02815566) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.